Global and China Cutaneous Leishmaniasis Drugs Market Insights, Forecast to 2027

Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.

Market Analysis and Insights: Global and China Cutaneous Leishmaniasis Drugs Market
This report focuses on global and China Cutaneous Leishmaniasis Drugs market.
In 2020, the global Cutaneous Leishmaniasis Drugs market size was US$ 41 million and it is expected to reach US$ 55 million by the end of 2027, with a CAGR of 4.1% during 2021-2027. In China the Cutaneous Leishmaniasis Drugs market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Cutaneous Leishmaniasis Drugs Scope and Market Size
Cutaneous Leishmaniasis Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Cutaneous Leishmaniasis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Cutaneous Leishmaniasis Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs

Segment by Application
Hospital
Retail Pharmacy
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma